Daiichi Sankyo

20 for 2020 – Five pharma companies to watch

The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... 4. Daiichi Sankyo. The fourth company on our list – Daiichi Sankyo – has something in common with the first.Our

AZ revenues rise, but it says coronavirus could hit 2020

However, the FDA approval of Daiichi Sankyo-partnered HER2 drug Enhertu (trastuzumab deruxtecan) for breast cancer – tipped as a $4.5bn blockbuster by some analysts – came too late to register any

Roche posts minor sales miss in Q4 as biosimilar pressure grows

the latter is facing new competition from AstraZeneca/Daiichi Sankyo’s recently-approved  Enhertu (trastuzumab deruxtecan).

AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer

Improved overall survival when compared to chemotherapy. AstraZeneca and Daiichi Sankyo say new Enhertu data in gastric cancer could be enough to file for approval, potentially adding another indication to its ... The two companies are splitting

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]